Tide turns for Sosei's neuropathic pain contender as Chinese firm picks up rights
This article was originally published in Scrip
Sosei has divested its global rights to a product candidate for neuropathic pain to China's Beijing Tide Pharmaceutical, in a move the Japanese firm said was prompted by a need to prioritise its limited development resources.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.